Absorica Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

• News
• Research
• Blogs
• Podcasts
• Alerts
• Clinical Trials
• Forums

Isotretinoin (13- Cis-Retinoic Acid) Versus Spike Protein Based Vaccine for Providing Complete Protection Against COVID-19 and Preventing the Expected Long Term Serious Side Effects Which May Caused by Spike Protein Based Vaccine-An Urgent Protective Clinical Trial
Condition:   Covid19 Vaccine Interventions:   Drug: Oral 13 cis retinoic acid;   Drug: Aerosolized 13 cis retinoic acid;   Combination Product: 13 cis retinoic acid doses orally in combination with spike protein based vaccine;   Combination Product: Aerosolized 13 cis retinoic acid in combination with spike protein based vaccin e;   Biological: Biological: spike protein based vaccine such as ChAdOx1 nCoV-19 vaccine Sponsor:   Kafrelsheikh University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 29, 2021 Category: Research Source Type: clinical trials

Oral Isotretinoin and Covid-19 Infection
Conditions:   Isotretinoin Adverse Reaction;   Covid19 Intervention:   Sponsor:   University of Aberdeen Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 11, 2020 Category: Research Source Type: clinical trials